Articles by Dr. Sarah Mitchell
CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals
CRISPR Therapeutics reports CASGEVY now approved in 10 countries for severe sickle cell disease and beta thalassemia, reaching over 60,000 eligible patients worldwide.
mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026
New clinical trial data validates mBIOTA Elemental as effective IBS therapeutic, showing symptom improvement across all three IBS subtypes at DDW 2026.
Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients
Health Canada approves Novartis' Fabhalta (iptacopan) oral treatment for adults with complement 3 glomerulopathy, offering new hope for rare kidney disease patients.
ASCO 2026: Cellectar's Waldenström Macroglobulinemia Data
Cellectar Biosciences will present CLOVER WaM (iopofosine I 131) data at ASCO 2026, focusing on efficacy subset data in relapsed/refractory Waldenström macroglobulinemia.
Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026
Cytokinetics announces topline results from pivotal ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy on May 5, 2026.
Excipient World Conference: Key Highlights and Industry Trends
The Excipient World Conference 2026 highlighted major advances in pharma excipients, including innovations in drug delivery, regulatory compliance strategies, and sustainable formulation technologies shaping the future of pharmaceutical development.
APHL 2026 Annual Meeting: Day 1 Highlights
Day 1 of the APHL 2026 Annual Meeting featured discussions on innovative diagnostic approaches and collaborative strategies in public health laboratory science.
APHL 2026: Day 1 Highlights and Key Takeaways
Day 1 of APHL 2026 focused on innovations in public health laboratory practices and emerging technologies. The opening keynote addressed the importance of data-driven decision-making in public health.
THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs
The Health Management Academy has released 2026 strategic priorities for Chief Pharmacy Officers, emphasizing workforce resilience, AI governance, and revenue cycle optimization amid policy pressures and evolving market demands.
CPhI Americas 2026: Pharma Manufacturing Trends in Philadelphia
CPhI Americas 2026 returns to Philadelphia, focusing on pharmaceutical manufacturing trends, contract manufacturing, AI integration, and regulatory shifts. The event is a key meeting point for industry professionals to discuss the evolving landscape.
IPEC Americas Annual Meeting: Key Takeaways for Pharma
The IPEC Annual Meeting 2026 pharmaceutical event status remains unconfirmed by official sources. Pharma professionals should monitor the International Pharmaceutical Excipients Council for updates on this critical industry conference addressing excipient innovation, regulatory compliance, and supply chain resilience.
Excipient World Conference: Day 1 Highlights
The Excipient World Conference 2026 opened with industry-wide focus on pharmaceutical excipient innovations, regulatory compliance, and supply chain collaboration. Day 1 featured presentations on advanced drug delivery systems, stability enhancement technologies, and evolving global standards for excipient qualification.
APHL 2026 Annual Meeting: Key Takeaways from Day 1
Day 1 of the APHL 2026 Annual Meeting highlighted advancements in public health laboratory science and the importance of collaboration, covering topics from infectious disease control to laboratory technology innovations. Networking events fostered discussions and partnerships to tackle public health challenges.
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
XtalPi and PharmaEngine's AI-discovered PRMT5 inhibitor PEP08 starts Phase I solid tumor trial enrollment, marking a key milestone in synthetic lethality cancer treatment.
Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science
Everads Therapy reports favorable safety and tolerability data for its novel suprachoroidal drug delivery device in first-in-human trial published in peer-reviewed journal.
IPEC Annual Meeting 2026: No Pharma News Today
No official confirmation or breaking pharmaceutical news from the IPEC Annual Meeting 2026 is currently available in public sources. Pharmaceutical professionals should verify event status directly with the International Pharmaceutical Excipients Council.
Excipient World Conference 2026: No Pharma Breaking News
The Excipient World Conference 2026 has not generated breaking pharmaceutical news as of May 4, 2026. However, emerging market trends in lipid-based vitamin C, natural oil excipients, and biodegradable packaging solutions provide strategic insights for pharma excipient professionals.
APHL 2026 Annual Meeting Opens: Public Health Lab Focus
The APHL 2026 Annual Meeting commenced today in Baltimore, MD, bringing together public health laboratory leaders, scientists, and partners to discuss critical issues and advancements in the field. The conference, running from May 4–7, will address key trends in laboratory science and public health.
MHRA Post-Brexit Drug Approval: What You Need to Know
Learn about the MHRA's new drug approval process post-Brexit and its impact on the availability of essential medications like Ozempic for diabetes.
MHRA Divergence from EMA: What You Need to Know for EU Market Access
This article explores the key differences between MHRA and EMA regulations, focusing on how they affect market access for drugs like XYZ in the EU.